CCM
BBP icon

Coldstream Capital Management’s Virtus Biotech ETF BBP Stock Holding History

Coldstream Capital Management’s Portfolio BBP Stock Details BBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,285
Closed -$211K – 837
2022
Q4 		$211K Buy
+4,285
New +$205K 0.01% 747
2022
Q2 		$328K Buy
+7,955
New +$316K 0.01% 533

Other funds holding BBP

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
DSC
Duncker Streett & Co St. Louis, Missouri $526M AUM 22.2% 1-Year Est. Return

Coldstream Capital Management's BBP Position: Q1 2023 in Review

Coldstream Capital Management sold out of Virtus Biotech ETF (BBP) in Q1 2023, closing a stake of 4,285 shares — an estimated $211K sold.

Coldstream Capital Management first reported a position in BBP in Q2 2022 and held it in 2 quarters. The position peaked at $328K in Q2 2022. 14 funds tracked by Wall St. Rank hold BBP as of Q1 2023.

  • Coldstream Capital Management reported no remaining Virtus Biotech ETF position as of Q1 2023 after selling out during the quarter.
  • Coldstream Capital Management sold 4,285 Virtus Biotech ETF shares in Q1 2023, an estimated $211K.
  • Coldstream Capital Management first reported a position in Virtus Biotech ETF in Q2 2022 and held it in 2 quarters.
  • Coldstream Capital Management's Virtus Biotech ETF position peaked at $328K in Q2 2022.
  • 14 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q1 2023.

Based on Coldstream Capital Management's 13F filing for Q1 2023, filed 15 May 2023.